Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that the company completed enrollment in the FOCUS trial, an international Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE